PCa Commentary #215 – Low Testosterone After Successful Treatment – Is Replacement Testosterone Safe?

by Dr. Ed Weber | Jul 29, 2026 | PCa Commentary

Any man who has undergone androgen deprivation therapy – ADT – to suppress his prostate cancer will have suffered some or all the associated adverse effects of diminished testosterone: fatigue, hot flushes, cognitive decline, bone density loss, erectile...

PCa Commentary #214 – Artera AI — “Prostate Test”: A Validated Tool to Assist in Treatment Decisions.

by Dr. Ed Weber | Jun 9, 2026 | PCa Commentary

  After a biopsy diagnosis of prostate cancer, supported by an MRI and Ga 68PET/CT, if the disease is localized to the prostate, the initial decision is whether to treat the cancer with surgery or radiation therapy or defer to active surveillance. Treatment is...

PCa Commentary #213 – METASTASIS DIRECTED THERAPY (MDT) — A Second Chance for Long-Term Disease Control With or Without Androgen Depression. And New Strategies for Avoiding ADT.

by Dr. Ed Weber | May 26, 2026 | PCa Commentary

Following primary therapy with surgery or radiation in men with high-intermediate-risk and high-risk prostate cancer at diagnosis, the disease will recur in 20 – 30%. The recurrences may involve a small number of metastatic lesions, <5 sites or a few more....

PCa Commentary #212 – Mutations in DNA Damage Repair Genes – What Are They and Their Clinical Significance

by Dr. Ed Weber | Apr 8, 2026 | PCa Commentary

Identifying mutations in the DNA Damage Repair (DDR) genes BRCA 1 & 2, ATM, PALB2 and CHEK2 carries clinical significance and opportunities. These genes (and several others) cooperate in repairing single-and double-strand DNA breaks, that if not corrected, impair...

PCa Commentary #211 – OSTEOPOROSIS: Androgen Suppression’s Unseen Liability

by Dr. Ed Weber | Feb 19, 2026 | PCa Commentary

Androgen Deprivation Therapy, (ADT) for Treatment of Prostate Cancer can lead to an unseen liability, loss of bone density or osteoporosis. Prostate cancer suppression with Lupron and other testosterone lowering agents (ADT) has been long-recognized and widely...

PCa Commentary #210 – Metastases Directed Therapy (MDT) — An Update: Second Chance for Long-term Disease Control

by Dr. Ed Weber | Feb 19, 2026 | PCa Commentary

A world-wide meta-analysis of the efficacy and safety of MDT in treatment of oligometastatic prostate cancer (omPC) was presented at the 2025 ASCO Genitourinary Cancers Symposium by Chad Tang comparing MDT+ ADT + Androgen Receptor Pathway Inhibitors (ARPI; i.e.,...